Last checked at 6 Feb 2024 07:00
06 February 2024
ECO Animal Health Group plc
("ECO" or the "Company")
Trademark Approval for ECOVAXXIN® family in the EU
ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, is pleased to announce that the ECOVAXXIN® trademark has been approved by the European Union ("EU").
In addition to this EU trademark ECOVAXXIN® has also been registered in the USA and in the UK, giving extensive protection in key markets for animal health products.
The registration for ECOVAXXIN® provides trademark branding for a family of vaccine products. ECOVAXXIN® is a master trademark and will protect all ECO's forthcoming vaccine products. Starting in 2025, the Company plans to market its vaccine products in multiple jurisdictions, with multiple planned launches over the next ten year period.
The first two planned products to carry the trademark will be the Company's poultry mycoplasma vaccines, specifically ECOVAXXIN® MS, a vaccine against Mycoplasma Synoviae, and ECOVAXXIN® MG, a vaccine against Mycoplasma Gallisepticum.
The trademark approval supports ECO's strategy of accelerating growth through the Company's research and development pipeline. The addition of new vaccines is expected to significantly support sales and profit growth over the next ten years.
David Hallas, Chief Executive Officer of ECO Animal Health Group plc, commented: "This trademark approval, complemented by registrations in the USA and the UK, provides broad protection for the ECOVAXXIN® family, fortifying our commitment to advancing growth through innovative vaccine products and supporting our strategic focus on R&D-driven expansion at ECO Animal Health Group plc."
-Ends-
For further information please contact:
|
About ECO Animal Health
ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.
Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.
Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry.
Click here for more information: https://ecoanimalhealth.com